SWOG clinical trial number
CTSU/NRG-GY020

A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

Open
Phase
Abbreviated Title
Testing the addition of the immunotherapy drug, pembrolizumab, to the usual radiation treatment for newly diagnosed early stage high intermediate risk endometrial cancer
Activated
02/07/2020
Participants
CTSU

Research committees

Early Therapeutics & Rare Cancers

Treatment

MK-3475

Eligibility Criteria Expand/Collapse

Please review protocol eligibility criteria on the CTSU website (http://www.ctsu.org/) for more information.

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/AOST2032

AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/17/2023
Open
SWOG Clinical Trial Number
CTSU/AOST2031

AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/15/2022
Open
SWOG Clinical Trial Number
S2012

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12/02/2021
Accrual
34%
Open
Phase